Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 168 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential andScope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cytomegalovirus (HHV-5) Infections Overview 9
Therapeutics Development 10
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 16
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 22
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 25
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 26
3-V Biosciences, Inc. 26
AIMM Therapeutics B.V. 27
AlphaVax, Inc. 28
Altor BioScience Corporation 29
Applied Immune Technologies Ltd 30
Astellas Pharma Inc. 31
BioApex, s.r.o. 32
Bionor Pharma ASA 33
Biotest AG 34
CAP-CMV GmbH 35
Cell Medica Limited 36
Chimerix, Inc. 37
GlaxoSmithKline plc 38
Hookipa Biotech AG 39
Humabs BioMed SA 40
INAGEN ApS 41
iQur Ltd. 42
Kadmon Corporation, LLC 43
Lead Discovery Center GmbH 44
Merck & Co., Inc. 45
Microbiotix, Inc. 46
Novartis AG 47
Pfizer Inc. 48
Phoenix Biotechnology, Inc. 49
Spider Biotech 50
Trellis Bioscience, Inc. 51
Vakzine Projekt Management GmbH 52
VBI Vaccines Inc. 53
Vical Incorporated 54
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
AL-18 - Drug Profile 64
Antibody to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 65
Antiviral TCR-Ck - Drug Profile 66
Antiviral TCR-Ig - Drug Profile 67
ASP-0113 - Drug Profile 68
AVX-601 - Drug Profile 69
BA-368 - Drug Profile 71
brincidofovir - Drug Profile 72
BT-084 - Drug Profile 74
CAPCMV-001 - Drug Profile 75
Cell Therapy 3 For CMV - Drug Profile 76
Cell Therapy for CMV Infections - Drug Profile 77
Cell Therapy for Cytomegalovirus (HHV-5) Infections - Drug Profile 78
Cell Therapy for Cytomegalovirus Infections - Drug Profile 79
Cell Therapy for Cytomegalovirus Infections - Drug Profile 80
Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile 81
Cell Therapy for Infectious Disease - Drug Profile 82
Cell Therapy for Infectious Diseases - Drug Profile 83
Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 84
Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 86
CMX-669 - Drug Profile 87
CSJ-148 - Drug Profile 88
CyMVectin - Drug Profile 89
cytomegalovirus (virus like particle) vaccine - Drug Profile 90
cytomegalovirus vaccine - Drug Profile 91
cytomegalovirus vaccine - Drug Profile 92
Cytomegalovirus vaccine - Drug Profile 93
cytomegalovirus vaccine - Drug Profile 94
cytomegalovirus vaccine 1 - Drug Profile 95
Cytovir-CMV - Drug Profile 97
Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 99
Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 100
Drug for Cytomegalovirus - Drug Profile 101
filociclovir - Drug Profile 102
Gene Therapy for Cytomegalovirus Infections - Drug Profile 104
HB-101 - Drug Profile 105
LDC-4297 - Drug Profile 106
letermovir - Drug Profile 107
maribavir - Drug Profile 108
MBX-2168 - Drug Profile 110
Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 111
Monoclonal Antibody for HCMV Infections - Drug Profile 112
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 113
Protein For Cytomegalovirus Infections - Drug Profile 114
RBT-301 - Drug Profile 115
Recombinant Peptide for Infectious Diseases - Drug Profile 116
RKP-00156 - Drug Profile 117
SB-105A10 - Drug Profile 118
Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile 120
Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile 121
Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile 122
Small Molecules for CMV Infections - Drug Profile 123
Small Molecules for Viral Infections - Drug Profile 124
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 125
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 126
Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile 127
TRL-345 - Drug Profile 128
V-160 - Drug Profile 129
Vacc-CMV - Drug Profile 130
VBI-1501A - Drug Profile 131
Viralym-C - Drug Profile 132
VPM-2001 - Drug Profile 133
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 134
Cytomegalovirus (HHV-5) Infections - Dormant Projects 152
Cytomegalovirus (HHV-5) Infections - Discontinued Products 156
Cytomegalovirus (HHV-5) Infections - Product Development Milestones 157
Featured News & Press Releases 157
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 163
Disclaimer 164

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2015 14
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Comparative Analysis by Unknown Stage Development, H1 2015 25
Products under Development by Companies, H1 2015 26
Products under Development by Companies, H1 2015 (Contd..1) 27
Products under Development by Companies, H1 2015 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2015 29
Cytomegalovirus (HHV-5) Infections - Pipeline by 3-V Biosciences, Inc., H1 2015 30
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2015 31
Cytomegalovirus (HHV-5) Infections - Pipeline by AlphaVax, Inc., H1 2015 32
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2015 33
Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H1 2015 34
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2015 35
Cytomegalovirus (HHV-5) Infections - Pipeline by BioApex, s.r.o., H1 2015 36
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2015 37
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2015 38
Cytomegalovirus (HHV-5) Infections - Pipeline by CAP-CMV GmbH, H1 2015 39
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2015 40
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2015 41
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline plc, H1 2015 42
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2015 43
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2015 44
Cytomegalovirus (HHV-5) Infections - Pipeline by INAGEN ApS, H1 2015 45
Cytomegalovirus (HHV-5) Infections - Pipeline by iQur Ltd., H1 2015 46
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2015 47
Cytomegalovirus (HHV-5) Infections - Pipeline by Lead Discovery Center GmbH, H1 2015 48
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2015 49
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2015 50
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2015 51
Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc., H1 2015 52
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2015 53
Cytomegalovirus (HHV-5) Infections - Pipeline by Spider Biotech, H1 2015 54
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2015 55
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2015 56
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc., H1 2015 57
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2015 58
Assessment by Monotherapy Products, H1 2015 59
Number of Products by Stage and Target, H1 2015 61
Number of Products by Stage and Mechanism of Action, H1 2015 63
Number of Products by Stage and Route of Administration, H1 2015 65
Number of Products by Stage and Molecule Type, H1 2015 67
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2015 138
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2015 156
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2015 157
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H1 2015 158
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H1 2015 159
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2015 160